文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-pentixafor PET/CT在原发性醛固酮增多症伴双侧病变患者中的临床价值:单中心研究的初步结果

Clinical value of 68Ga-pentixafor PET/CT in patients with primary aldosteronism and bilateral lesions: preliminary results of a single-centre study.
PubMed 文献 · EJNMMI Res · 2024-07-04

该研究回顾性纳入25例CT显示双侧病变的原发性醛固酮增多症患者,评估68Ga-pentixafor PET/CT在诊断和预后中的价值。68Ga-pentixafor PET/CT与肾上腺静脉采血的侧化一致率为65.2%(15/23),其侧化结果支持20例患者的临床决策,其中90%治疗有效。显性侧SUVmax在手术患者中高于药物治疗患者,KCNJ5突变组SUVmax高于野生组,摄取值与KCNJ5基因状态相关。

要点

  • 68Ga-pentixafor PET/CT与肾上腺静脉采血侧化一致率为65.2%(15/23)。
  • PET/CT侧化结果支持20例患者临床决策,其中90%治疗有效。
  • 手术患者显性侧SUVmax高于药物治疗患者,KCNJ5突变组SUVmax高于野生组。

核心结论

  • 68Ga-Pentixafor PET/CT对CT显示双侧病变的原发性醛固酮增多症患者有益。
  • 基于PET侧化结果的治疗总体有效。
  • 68Ga-Pentixafor PET/CT与KCNJ5基因状态存在一定关系,需进一步分析。

研究设计与样本

  • 回顾性评估25例CT显示双侧病变的原发性醛固酮增多症患者。
  • 所有患者均接受68Ga-Pentixafor PET/CT和肾上腺静脉采血。
  • 分析双侧肾上腺病变SUVmax、双侧肾上腺病变SUVmax比值(CON)与临床诊断、治疗结局及KCNJ5基因状态的关系。

主要发现

  • 68Ga-Pentixafor PET/CT与肾上腺静脉采血的侧化一致率为65.2%(15/23)。
  • 68Ga-pentixafor PET/CT的侧化结果支持20例原发性醛固酮增多症患者的临床决策,其中90%显示治疗有效。
  • 手术治疗的惠者显性侧SUVmax高于药物治疗患者。
  • KCNJ5突变组SUVmax高于KCNJ5野生组,68Ga-Pentixafor摄取值与KCNJ5基因状态相关。

关键数值与推荐

  • 68Ga-Pentixafor PET/CT与肾上腺静脉采血侧化一致率为65.2%(15/23)。
  • PET/CT侧化结果支持20例患者临床决策,其中90%治疗有效。
  • 手术患者显性侧SUVmax高于药物治疗患者。
  • KCNJ5突变组SUVmax高于KCNJ5野生组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Subtype diagnosis of primary aldosteronism (PA) is used to determine treatment, and the potential utility of 68Ga-pentixafor PET/CT for investigation of PA has long been recognized. The study aimed to evaluate the clinical value of 68Ga-pentixafor PET/CT in the diagnosis and prognosis of patients with bilateral lesions identified by CT. METHODS: In total, 25 patients with PA and bilateral lesions on CT were retrospectively evaluated. All patients underwent 68Ga-Pentixafor PET/CT and adrenal vein sampling. The analysis focused on establishing the relationship between bilateral adrenal lesions SUVmax and the ratio of bilateral adrenal lesions SUVmax (CON) and clinical diagnosis, treatment outcomes, and KCNJ5 gene status. RESULTS: The concordance rate between 68Ga-Pentixafor PET/CT and adrenal venous sampling was 65.2% (15/23). The lateralization results of 68Ga-pentixafor PET/CT supported the clinical decisions of 20 patients with PA, 90% of whom showed effectiveness in treatment. The SUVmax on the dominant side of the surgically treated patients was higher than that of patients treated with drugs. The SUVmax of the KCNJ5 mutant group was higher than that of the KCNJ5 wild group, and 68Ga-Pentixafor uptake was correlated with KCNJ5 gene status. CONCLUSIONS: 68Ga-Pentixafor PET/CT proves beneficial for patients with PA with bilateral lesions on CT. The treatment is generally effective based on the results of PET lateralization. Simultaneously, a certain relationship exists between 68Ga-Pentixafor PET/CT and KCNJ5 gene status, warranting further analysis.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Zuo R, Liu S, Li W, et al. Clinical value of 68Ga-pentixafor PET/CT in patients with primary aldosteronism and bilateral lesions: preliminary results of a single-centre study. EJNMMI Res. 2024. PMID: 38965078. doi:10.1186/s13550-024-01125-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。